Lion Biotechnologies appoints Gregory Schiffman as CFO
Mr. Schiffman brings fifteen years of experience leading the financial operations and strategy of publicly-traded healthcare companies such as Dendreon, Affymetrix and Applied Biosystems.
Most recently, he was Executive Vice President and CFO of StemCells, Inc, a cell-based therapeutics company where he oversaw all activities related to finance and accounting, information technology, and corporate communications.
In his previous positions, in addition to his finance and accounting duties, he also was responsible for the implementation of commercial infrastructure processes and systems, supply chain logistics, procurement and manufacturing.
Prior to StemCells, Mr. Schiffman was the Executive Vice President and CFO of Dendreon Corporation, a publicly traded biotechnology company engaged in the discovery, development and commercialization of novel therapeutics cellular immunotherapy and small molecule products.
Before entering the healthcare industry, Mr. Schiffman held roles of increasing responsibility during his eleven year term with Hewlett Packard, including serving as controller of its European personal computer manufacturing and distribution operations in Grenoble, France, and as manufacturing manager and controller of its Netmetrix Division.
Mr. Schiffman holds a bachelor's degree in accounting from De Paul University and an MBA from the Kellogg Graduate School of Management at Northwestern University. He also is a CPA in Illinois. ■
LATEST MOVES FROM New York
- American Express appoints Stephen J. Squeri as CEO and chairman
- AzurRx BioPharma appoints Vern Lee Schramm to board
- Nature's Bounty appoints Mark Gelbert as CSO
- Global Net Lease appoints Christopher J. Masterson as CFO
- Bristol-Myers Squibb appoints Saurabh Saha as SVP
More inside POST